Medicine guide
Abecma
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Idecabtagene vicleucel
- Made by
- Bristol-Myers Squibb Pharma EEIG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Bristol-Myers Squibb Pharma EEIG |
|---|---|
| Active substance | Idecabtagene vicleucel |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01 · Cancer treatments and immune-system medicines |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2021-08-18 |
| Last updated by the regulator | 2025-12-09 |
| EMA product number | EMEA/H/C/004662 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).